Social workers are increasingly interested in psychedelic-assisted therapy, but face unique practical and ethical challenges. The article outlines key considerations including legal barriers, the need for specialized training, ethical obligations around informed consent and safety, and the importance of addressing systemic inequities in access. It emphasizes that social workers must integrate their profession's core values of social justice and client self-determination into this emerging treatment model. The piece provides guidance on navigating regulatory uncertainty, preparing clients, and ensuring culturally competent care.
MDMA, LSD, and psilocybin have received 'Breakthrough Therapy' designation from the FDA and are moving into Phase 3 clinical trials, bringing legal administration for mental health treatment closer. Research from Lykos, Usona Institute, Mindmed, Compass Pathways, and Johns Hopkins shows promising efficacy when psychedelic compounds are paired with psychotherapy, with participants no longer meeting diagnostic criteria for conditions like major depressive disorder, treatment-resistant depression, and PTSD compared to placebo groups also receiving psychotherapy. Several states, including Oregon and Colorado, have legalized supervised therapeutic use of psilocybin, and other states consider decriminalizing plant-based medicines, creating demand for therapy providers with varying levels of psychedelic familiarity.